Lonza Group AG Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 1/30/2026)
| Balance Sheet | Total Assets | 18,967,000,000.00 | ROE | 48.16 % |
| Balance Sheet | Total Equity | 9,134,000,000.00 | ROA | 5.00 % |
| Cashflow | Capital Expenditures | -1,373,000,000.00 | P/FCF | -189.23 |
| Cashflow | Free Cash Flow | -217,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 1,156,000,000.00 | P/CF | 35.52 |
| Income | Earnings per Share (diluted) | 13.53 | Div. Yield | 0.68 % |
| Income | Net Income | 949,000,000.00 | P/E | 43.27 |
| Income | Shares Outstanding | 69,940,800.00 | P/B | 4.50 |
| Income | Total Revenue | 6,531,000,000.00 | P/S | 6.29 |
Ratios calculated on: 10/14/2026
Company Description
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. It offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to dosage forms for the pharma and consumer health, and nutrition industries, as well as develops cell and gene therapies. The company also provides drinking water sanitizers, nutraceuticals, antidandruff agents, and other personal care ingredients; and agricultural products and advanced coatings and composites, as well as microbial control solutions that combat dangerous viruses, bacteria, and other pathogens. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.lonza.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more